Skip to main content
GutCited

L-Glutamine için Crohn's Disease

C

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Sonuç

Small RCTs show glutamine (0.5 g/kg/day) improves intestinal permeability and morphology in Crohn's patients. Evidence limited by small sample sizes.

Key Study Findings

Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None vs: None Outcome: Gut microbiota composition Etki: None None

Popülasyon: Crohn's disease patients

Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None vs: None Outcome: Cholesterol levels Etki: None None

Popülasyon: Mouse model

Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT) vs: Pre-treatment baseline Outcome: Clinical remission and multi-omics changes Etki: None None

Popülasyon: Patients with Crohn's disease

In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic) vs: Wild-type mice Outcome: Cytokine production in macrophage activation Etki: None None

Popülasyon: Beclin1 variant mice + AIEC infection

Observational Study n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured) vs: Healthy controls (n=126) Outcome: PAGln association with CD and colitis Etki: None None

Popülasyon: New-onset treatment-naive CD (n=136) + controls

Observational Study
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Dose: None vs: None Outcome: CAM use patterns in IBD patients Etki: None None

Popülasyon: Brazilian IBD patients

Key Statistics

3

Çalışmalar

200

Katılımcılar

Positive

C

Derece

Referenced Papers

The Cochrane database … 2018 425 atıf
Gastroenterology clinics of … 2018 67 atıf
Current opinion in … 2017 37 atıf
The Cochrane database … 2016 37 atıf
The Cochrane database … 2007 192 atıf
Current opinion in … 2005 22 atıf
Clinical nutrition (Edinburgh, … 2004 18 atıf
Alimentary pharmacology & … 2003 179 atıf
Revista do Hospital … 2002 39 atıf
Current opinion in … 2002 1 atıf
Current opinion in … 2002
The Cochrane database … 2001 149 atıf
Current opinion in … 2000 21 atıf
Zeitschrift fur Gastroenterologie 1998 18 atıf
Schweizerische medizinische Wochenschrift. … 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:
5-15 g/day
ibsdsupport:
5 g three times daily (15 g/day total)
postexercisegut:
0.25-0.9 g/kg before intense exercise
gutbarriersupport:
0.5 g/kg/day (approximately 30-40 g/day for adults)

Üst sınır: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Positive --
None -- Positive --
Washed microbiota transplantation (WMT) -- Positive --
Beclin1 constitutive activation (genetic) -- Positive --
Phenylacetylglutamine (PAGln, measured) -- Negative 262
None -- Mixed --
None -- Negative --
None -- Mixed --

En iyi alım zamanı: Between meals or before exercise; divide doses throughout the day

Safety & Side Effects

Bildirilen Yan Etkiler

  • Mild gastrointestinal discomfort at high doses
  • Headache
  • Dizziness at very high doses
  • Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)

Bilinen Etkileşimler

  • Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
  • Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
  • Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)

Tolere edilebilir üst alım: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does L-Glutamine help with Crohn's Disease?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-Glutamine may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.